Equities Analysts Issue Forecasts for Oculis FY2025 Earnings

Oculis Holding AG (NASDAQ:OCS) – Leerink Partnrs raised their FY2025 earnings per share (EPS) estimates for Oculis in a research note issued on Tuesday, November 11th. Leerink Partnrs analyst M. Goodman now expects that the company will earn ($2.38) per share for the year, up from their previous estimate of ($2.51). The consensus estimate for Oculis’ current full-year earnings is ($2.09) per share. Leerink Partnrs also issued estimates for Oculis’ Q4 2025 earnings at ($0.50) EPS, FY2026 earnings at ($1.69) EPS, FY2027 earnings at ($3.63) EPS, FY2028 earnings at ($1.38) EPS and FY2029 earnings at $0.06 EPS.

Several other equities analysts have also recently issued reports on OCS. Wall Street Zen upgraded Oculis from a “sell” rating to a “hold” rating in a research report on Saturday. Chardan Capital reiterated a “buy” rating and issued a $51.00 price target on shares of Oculis in a research report on Tuesday, November 11th. Bank of America lowered their price objective on shares of Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a research note on Thursday. HC Wainwright increased their target price on shares of Oculis from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday, November 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Oculis in a report on Wednesday, October 8th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Oculis has an average rating of “Moderate Buy” and an average price target of $39.80.

Oculis Price Performance

NASDAQ OCS opened at $19.60 on Friday. The firm has a market capitalization of $1.03 billion, a PE ratio of -7.78 and a beta of 0.30. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.47 and a quick ratio of 4.55. Oculis has a 12 month low of $14.00 and a 12 month high of $23.08. The company’s 50 day simple moving average is $19.20 and its 200 day simple moving average is $18.64.

Oculis (NASDAQ:OCS) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.10. Oculis had a negative net margin of 12,915.42% and a negative return on equity of 80.82%. The business had revenue of $0.31 million during the quarter, compared to the consensus estimate of $0.23 million.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Kestra Private Wealth Services LLC acquired a new stake in shares of Oculis during the 1st quarter valued at $234,000. Bosun Asset Management LLC purchased a new stake in shares of Oculis during the 2nd quarter worth about $378,000. Marshall Wace LLP acquired a new stake in shares of Oculis during the 2nd quarter valued at about $393,000. Geode Capital Management LLC grew its stake in shares of Oculis by 27.7% in the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after buying an additional 6,384 shares in the last quarter. Finally, Bank of America Corp DE grew its stake in shares of Oculis by 2.2% in the 2nd quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock valued at $786,000 after buying an additional 878 shares in the last quarter. Institutional investors and hedge funds own 22.30% of the company’s stock.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.